ClinicalTrialsFinder
RecruitingNot ApplicableNCT04047953

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

The Study of Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Initial Unresectable Local Advanced or Potentially Resectable Metastatic Gastric Adenocarcinoma

Sponsor

Peking University Cancer Hospital & Institute

Enrollment

95 participants

Start Date

Sep 10, 2019

Study Type

INTERVENTIONAL

Conditions

Gastric Adenocarcinoma

Summary

To evaluate the efficacy and safety of Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 conversion therapy for initial unresectable local progression or potential resectable metastatic gastric adenocarcinoma.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria10

  • Age of 18-75 years; male or female.
  • Karnofsky Performance Status Score ≥70.
  • Histological diagnosis of gastric adenocarcinoma, HER2 expression negative.
  • The initial unresectable locally advanced or potentially resectable metastatic gastric adenocarcinoma, potentially resectable factor includes a single liver metastases, localized abdominal para-aortic lymph node (16a1 / b2) metastasis or positive abdominal free cancer cells.
  • Physical condition and organ function allow for larger abdominal surgery.
  • Subject baseline blood routine and blood biochemistry indexes meet the following criteria: hemoglobin(HB) ≥90 g/L; absolute neutrophil count(ANC) ≥1.5×109 /L; platelet count(PLT) ≥100×109 /L; alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤2.5 x upper limit of normal range (ULN); total bilirubin (TBIL)≤1.5 x upper limit of normal range (ULN); Creatinine(Cr)≤1.5 x upper limit of normal range(ULN); Serum albumin≥30g/L.
  • Echocardiographic scan confirmed left ventricular ejection fraction (LVEF) ≥ 50%.
  • No serious accompanying disease lead to a survival period of \<5 years.
  • Agree and be able to follow the protocol during the study period.
  • Written informed consent was provided prior to the study screening and the patient was informed that the study could be withdrawn at any time during the study without any loss.

Exclusion Criteria16

  • For the treatment of the gastric cancer, patients who have received cytotoxic chemotherapy, radiotherapy or immunotherapy, except corticosteroids.
  • Pregnancy or breastfeeding woman.
  • Women of childbearing age who had a positive pregnancy test at baseline or who did not undergo a pregnancy test. Menopausal women must be stopped for at least 12 months to ensure that no pregnancy is possible.
  • Men and women who have sex (with fertility probability) are reluctant to contraception during the study.
  • Patients with ascites and positive abdominal free cancer cells.
  • There are other history of malignant disease in the last 5 years, except for cured skin cancer and cervical carcinoma in situ.
  • Those with a history of epilepsy, central nervous system disease, or mental disorder may be judged by the investigator that their clinical severity may hinder the signing of informed consent or affect the patient's oral medication compliance.
  • Clinically severe (active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe drug-affected arrhythmias, or there is a history of myocardial infarction in the last 12 months.
  • Upper gastrointestinal stagnation or abnormal physiological function or malabsorption syndrome may affect the absorption of S-1.
  • It is known to have peripheral neuropathy ≥ NCI CTC AE grade 2. However, only the deep sputum reflex (DTR) disappears and the patient does not have to be excluded.
  • Organ transplantation requires immunosuppressive therapy.
  • Severe uncontrolled recurrent infections, or other serious uncontrolled concomitant diseases.
  • Moderate or severe renal impairment \[creatinine clearance equal to or lower than 50ml/min (calculated according to Cockcroft and Gault equations), or serum creatinine \> upper normal limit (ULN).
  • Those suffering from dihydropyrimidine dehydrogenase (DPD) deficiency are known.
  • Those who are allergic to taxanes or any research ingredients.
  • Those who received research medications or preparations/treatments (ie, participated in other trials) within 4 weeks prior to enrollment.

Interventions

DRUGPaclitaxel (albumin-bound) combined with Oxaliplatin and S-1

Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg，bid, d1-14( BSA\<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA\>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.

Locations(1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04047953

Related Trials

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

NCT074546422 locations

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

NCT072829121 location

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT0700174810 locations

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

NCT057533061 location

Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection

NCT069437811 location